Circassia Pharmaceuticals Stock Price, News & Analysis (LON:CIR)

GBX 97 -2.10 (-2.12 %)
(As of 01/17/2018 12:47 PM ET)
Previous CloseGBX 99.10
Today's RangeGBX 93.29 - GBX 97
52-Week RangeGBX 76.75 - GBX 115.61
Volume4,897 shs
Average Volume60,501 shs
Market Capitalization£319.26 million
P/E Ratio-440.91
Dividend YieldN/A
BetaN/A

About Circassia Pharmaceuticals (LON:CIR)

Circassia Pharmaceuticals logoCircassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Receive CIR News and Ratings via Email

Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolLON:CIR
CUSIPN/A
Phone+44-1865-405560

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-440.909090909091
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.22)
Net IncomeN/A
Net Margins-161.75%
Return on Equity-20.37%
Return on Assets-15.76%

Miscellaneous

EmployeesN/A
Outstanding Shares333,470,000

Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions

What is Circassia Pharmaceuticals' stock symbol?

Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

Where is Circassia Pharmaceuticals' stock going? Where will Circassia Pharmaceuticals' stock price be in 2018?

4 analysts have issued twelve-month price targets for Circassia Pharmaceuticals' shares. Their predictions range from GBX 110 to GBX 180. On average, they expect Circassia Pharmaceuticals' share price to reach GBX 142.50 in the next twelve months. View Analyst Ratings for Circassia Pharmaceuticals.

Who are some of Circassia Pharmaceuticals' key competitors?

Who are Circassia Pharmaceuticals' key executives?

Circassia Pharmaceuticals' management team includes the folowing people:

  • Francesco Granata M.D., Non-Executive Chairman of the Board (Age 65)
  • Steven Harris, Chief Executive Officer, Executive Director (Age 50)
  • Julien Cotta, Chief Financial Officer, Executive Director, Company Secretary (Age 53)
  • Rod Hafner, Director and Senior Vice President Research & Development, Executive Director (Age 51)
  • Russell Cummings, Non-Executive Director (Age 51)
  • Jean-Jacques Garaud M.D., Senior Independent Non-Executive Director (Age 62)
  • Marvin S. Samson, Independent Non-Executive Director (Age 74)
  • Lota S. Zoth CPA, Independent Non-Executive Director (Age 57)

How do I buy Circassia Pharmaceuticals stock?

Shares of Circassia Pharmaceuticals and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals' stock price today?

One share of Circassia Pharmaceuticals stock can currently be purchased for approximately GBX 97.

How big of a company is Circassia Pharmaceuticals?

Circassia Pharmaceuticals has a market capitalization of £319.26 million.

How can I contact Circassia Pharmaceuticals?

Circassia Pharmaceuticals' mailing address is Northbrook House, Robert Robinson Avenue, OXFORD, OX4 4GA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-405560.


MarketBeat Community Rating for Circassia Pharmaceuticals (CIR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Circassia Pharmaceuticals (LON:CIR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 142.50GBX 142.50GBX 142.50GBX 143.50

Circassia Pharmaceuticals (LON:CIR) Consensus Price Target History

Price Target History for Circassia Pharmaceuticals (LON:CIR)

Circassia Pharmaceuticals (LON:CIR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/4/2018Peel HuntReiterated RatingHoldGBX 130View Rating Details
12/4/2017Numis SecuritiesReiterated RatingBuyGBX 180View Rating Details
9/28/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 120 -> GBX 110View Rating Details
4/25/2017Stifel NicolausReiterated RatingBuyGBX 150View Rating Details
6/21/2016BarclaysInitiated CoverageOverweightGBX 410 -> GBX 170View Rating Details
6/21/2016Royal Bank of CanadaDowngradeSector PerformerGBX 430 -> GBX 105View Rating Details
(Data available from 1/17/2016 forward)

Earnings

Earnings History for Circassia Pharmaceuticals (LON:CIR)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Circassia Pharmaceuticals (LON:CIR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Circassia Pharmaceuticals (LON:CIR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Circassia Pharmaceuticals (LON CIR) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Circassia Pharmaceuticals (LON:CIR)

Circassia Pharmaceuticals (LON CIR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2017Jean-Jacques GaraudInsiderSell77,500GBX 89£68,975
9/18/2015Swingland,CharlesInsiderSell754,548GBX 320£2,414,553.60
(Data available from 1/1/2013 forward)

Headlines

Circassia Pharmaceuticals (LON CIR) News Headlines

Source:
DateHeadline
Top High Growth LSE Stocks This MonthTop High Growth LSE Stocks This Month
finance.yahoo.com - December 26 at 9:48 AM
Circassia Pharmaceuticals (CIR) "Buy" Rating Reaffirmed at Numis SecuritiesCircassia Pharmaceuticals' (CIR) "Buy" Rating Reaffirmed at Numis Securities
www.americanbankingnews.com - December 25 at 9:28 PM
Tudorza   Meets Primary Endpoints in ASCENT Study - London South East (blog)Tudorza Meets Primary Endpoints in ASCENT Study - London South East (blog)
www.lse.co.uk - December 5 at 4:44 PM
AstraZenecas COPD Drug Succeeds in Label Expansion Study - NasdaqAstraZeneca's COPD Drug Succeeds in Label Expansion Study - Nasdaq
www.nasdaq.com - December 5 at 4:44 PM
AstraZenecas COPD Drug Succeeds in Label Expansion StudyAstraZeneca's COPD Drug Succeeds in Label Expansion Study
finance.yahoo.com - December 5 at 11:50 AM
Circassia Pharma Welcomes NICE Guidelines For Testing AsthmaCircassia Pharma Welcomes NICE Guidelines For Testing Asthma
www.morningstar.co.uk - November 29 at 10:12 AM
Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : November 27, 2017Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : November 27, 2017
finance.yahoo.com - November 27 at 6:17 PM
Why Circassia Pharmaceuticals Plc (LSE:CIR) Could Be A BuyWhy Circassia Pharmaceuticals Plc (LSE:CIR) Could Be A Buy
finance.yahoo.com - November 14 at 5:44 PM
Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : November 6, 2017Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : November 6, 2017
finance.yahoo.com - November 6 at 6:28 PM
Circassia Pharmaceuticals And Other High Growth StocksCircassia Pharmaceuticals And Other High Growth Stocks
finance.yahoo.com - November 4 at 7:34 AM
Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : October 23, 2017Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : October 23, 2017
finance.yahoo.com - October 23 at 5:49 PM
Circassia Pharmaceuticals Plc – Value Analysis (LONDON:CIR) : October 16, 2017Circassia Pharmaceuticals Plc – Value Analysis (LONDON:CIR) : October 16, 2017
finance.yahoo.com - October 16 at 5:57 PM
Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : October 13, 2017Circassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : October 13, 2017
finance.yahoo.com - October 13 at 5:49 PM
Circassia Pharmaceuticals Plc (LSE:CIR): Risks You Need To Consider Before BuyingCircassia Pharmaceuticals Plc (LSE:CIR): Risks You Need To Consider Before Buying
finance.yahoo.com - October 2 at 5:08 PM
Numis Securities Ltd Reaffirms "Buy" Rating for Circassia Pharmaceuticals PLC (CIR)Numis Securities Ltd Reaffirms "Buy" Rating for Circassia Pharmaceuticals PLC (CIR)
www.americanbankingnews.com - October 1 at 9:52 AM
Circassia Pharmaceuticals PLC (CIR) Receives "Hold" Rating from Peel HuntCircassia Pharmaceuticals PLC (CIR) Receives "Hold" Rating from Peel Hunt
www.americanbankingnews.com - October 1 at 9:52 AM
Circassia Pharmaceuticals PLC (CIR) Price Target Cut to GBX 110 by Analysts at J P Morgan Chase & CoCircassia Pharmaceuticals PLC (CIR) Price Target Cut to GBX 110 by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - September 30 at 4:44 PM
Circassia Pharmaceuticals Loss Narrows After Big Impairment Last YearCircassia Pharmaceuticals Loss Narrows After Big Impairment Last Year
www.morningstar.co.uk - September 27 at 7:29 PM
Should You Buy Circassia Pharmaceuticals Plc (LSE:CIR) Now?Should You Buy Circassia Pharmaceuticals Plc (LSE:CIR) Now?
finance.yahoo.com - September 15 at 5:35 PM
Circassia Pharma Launches Nasal Screening NIOX VERO In EuropeCircassia Pharma Launches Nasal Screening NIOX VERO In Europe
www.morningstar.co.uk - September 12 at 5:50 PM
Circassia Pharmaceuticals PLCs (CIR) "Buy" Rating Reaffirmed at Numis Securities LtdCircassia Pharmaceuticals PLC's (CIR) "Buy" Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - September 10 at 10:50 AM
J P Morgan Chase & Co Reiterates Neutral Rating for Circassia Pharmaceuticals PLC (CIR)J P Morgan Chase & Co Reiterates Neutral Rating for Circassia Pharmaceuticals PLC (CIR)
www.americanbankingnews.com - September 9 at 8:18 PM
TOP NEWS: AstraZeneca Sees Positive Duaklir, Tezepelumab Study Results - London South East (registration) (blog)TOP NEWS: AstraZeneca Sees Positive Duaklir, Tezepelumab Study Results - London South East (registration) (blog)
www.lse.co.uk - September 9 at 4:54 PM
UPDATE: AstraZeneca Says Imfinzi Trials Placed On Hold By US FDAUPDATE: AstraZeneca Says Imfinzi Trials Placed On Hold By US FDA
www.morningstar.co.uk - September 7 at 10:23 PM
Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary DiseaseCircassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease
www.streetinsider.com - September 7 at 3:22 AM
AstraZenecas Duaklir trial hits primary endpointsAstraZeneca's Duaklir trial hits primary endpoints
www.marketwatch.com - September 7 at 3:22 AM
Circassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary DiseaseCircassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease
finance.yahoo.com - September 7 at 3:22 AM
Woodford dented after AstraZeneca and Provident shares fall - Financial TimesWoodford dented after AstraZeneca and Provident shares fall - Financial Times
www.ft.com - July 31 at 2:34 AM
BRIEF-Circassia Pharmaceuticals fy revenues increased to 23.1 mln stgBRIEF-Circassia Pharmaceuticals fy revenues increased to 23.1 mln stg
www.reuters.com - April 26 at 9:50 PM
Circassia Gets Early Termination Of Waiting Period In AstraZeneca DealCircassia Gets Early Termination Of Waiting Period In AstraZeneca Deal
www.morningstar.co.uk - April 11 at 11:24 AM
Woodford-Backed Biopharma Stock Circassia Surges on Astra PactWoodford-Backed Biopharma Stock Circassia Surges on Astra Pact
www.bloomberg.com - March 17 at 3:47 PM
$230M deal: AstraZeneca forms COPD drugs collaboration$230M deal: AstraZeneca forms COPD drugs collaboration
www.bizjournals.com - March 17 at 3:47 PM
INVESCO PERPETUAL SELECT TRUST PLC - Half-year ReportINVESCO PERPETUAL SELECT TRUST PLC - Half-year Report
www.finanznachrichten.de - February 1 at 4:38 PM
Total Voting Rights Update - London South East (registration) (blog)Total Voting Rights Update - London South East (registration) (blog)
www.lse.co.uk - December 1 at 4:28 PM
UK Stocks-Factors to watch on Sept. 27UK Stocks-Factors to watch on Sept. 27
www.reuters.com - September 27 at 8:49 AM
Half Year 2016 Circassia Pharmaceuticals PLC Earnings Release - Time Not SuppliedHalf Year 2016 Circassia Pharmaceuticals PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 27 at 8:49 AM

SEC Filings

Circassia Pharmaceuticals (LON:CIR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Circassia Pharmaceuticals (LON CIR) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.